RxDoctor Payments Data

Craig Sclar, MD

Cardiology · San Diego, CANPI 1730114497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.

$7,259in general payments, 2019–2025

Across 359 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$861
  • AstraZeneca$707
  • Amgen$705
  • Novo Nordisk$570
  • Lilly USA, LLC$464
  • Novartis$370
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$7,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,259 in reported general payments places this provider in the 85th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$97,179
Medicare patients
764
Services billed
1,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$95,360
Amiodarone Hcl12$1,648
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$515
Metoprolol Succinate23$504
ClopidogrelClopidogrel Bisulfate22$322
Atorvastatin Calcium22$260
Nitroglycerin15$250
Losartan Potassium28$245
SotalolSotalol Hcl11$212
Lisinopril28$177
Carvedilol25$143
Metoprolol Tartrate16$127
Amlodipine Besylate21$120
Sotalol AfSotalol Hcl12$117
Hydrochlorothiazide17$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$290$95,36078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 cardiology providers in California.

Other cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →